Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.

[1]  D. V. Hoff,et al.  Cancer chemotherapy handbook , 1980 .

[2]  R. Dedrick,et al.  Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.

[3]  Y. Hayashi,et al.  Salivary excretion of 5-fluorouracil. I. Fluctuation of the saliva/plasma concentration ratio and salivary clearance in beagle dogs following bolus intravenous administration. , 1985, Chemical & pharmaceutical bulletin.

[4]  C. Erlichman,et al.  Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. , 1986, Cancer treatment reports.

[5]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[6]  G. Peters,et al.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. , 1988, Cancer research.

[7]  A. de Gramont,et al.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. , 1988, European journal of cancer & clinical oncology.

[8]  Y. Hayashi,et al.  Salivary excretion of 5-fluorouracil (5-FU). III. Non-linear kinetics of salivary excretion of 5-FU following bolus intravenous administration in rats. , 1988, Chemical & pharmaceutical bulletin.

[9]  F. Lévi,et al.  Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. , 1988, Cancer research.

[10]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Arbuck,et al.  Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer , 1989, Cancer.

[12]  F. Demard,et al.  5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. , 1989, British Journal of Cancer.

[13]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Diasio,et al.  Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. , 1990, Cancer research.

[15]  Salivary excretion of 5-fluorouracil (5-FU). V. Effect of 5-FU concentration in perfusate on the salivary excretion of 5-FU in perfused rat mandibular gland. , 1990, Chemical & pharmaceutical bulletin.

[16]  J. Willson,et al.  Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Slevin,et al.  A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. , 1991, British Journal of Cancer.

[18]  M. Barberi-Heyob,et al.  Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography. , 1992, Journal of chromatography.

[19]  A. Schalhorn,et al.  Clinical pharmacokinetics of fluorouracil and folinic acid. , 1992, Seminars in oncology.

[20]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Demard,et al.  Influence of sex and age on fluorouracil clearance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Cascinu,et al.  Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. , 1994, European journal of cancer. Part B, Oral oncology.

[23]  C. Lindqvist,et al.  Effect of anticancer drugs on patients with and without initially reduced saliva flow. , 1994, European journal of cancer. Part B, Oral oncology.

[24]  M. Slevin,et al.  Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. , 1994, British Journal of Cancer.

[25]  E. Gamelin,et al.  Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.

[26]  J. M. Joulia,et al.  Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[27]  J. M. Joulia,et al.  Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). , 1997, Anticancer research.